# A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

> **NCT06184568** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 349 (actual)

## Conditions studied

- Type 2 Diabetes
- Obesity

## Interventions

- **DRUG:** IBI362
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT06184568
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2025-09-17
- **Final completion:** 2026-06-30
- **Target enrollment:** 349 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06184568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06184568, "A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06184568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*